Introduction:
This article discusses the importance of improving supply chains for cell therapy manufacturing. Pluri, an allogeneic cell therapy company, emphasizes the need for advanced therapy manufacturers to diversify and collaborate closely with suppliers. The company’s CTO, Lior Raviv, shares his advice on building supply chains for allogeneic cell therapies, based on their experience in bringing these therapies through Phase III clinical trials.
- An important step in building supply chains for allogeneic cell therapies is understanding the potential market size for products based on donor cells.
- Pluri advises advanced therapy manufacturers to engage with regulators early in the development process to meet regulatory requirements across different territories.
- Reducing reliance on a single supplier for raw materials and technologies is crucial to prevent production disruptions and manage costs.
- Building strong relationships with suppliers allows for collaboration on new processes and rapid response to customer requirements.
- Supply chain insights from older biologic markets, such as monoclonal antibodies, can be applied to cell therapy shipping logistics.
Conclusion:
Improving cell therapy supply chains requires advanced therapy manufacturers to understand market potential, engage with regulators early, diversify suppliers, strengthen supplier relationships, and learn from other biologic markets. By implementing these strategies, manufacturers can enhance the efficiency and effectiveness of their cell therapy manufacturing processes.
